%0 Journal Article
%T Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy
%A Akira Hashimoto
%A Setsuya Aiba
%A Taku Fujimura
%A Yota Sato
%A Yumi Kambayashi
%J Archive of "Case Reports in Oncology".
%D 2018
%R 10.1159/000488236
%X Bexarotene is a third-generation retinoid X receptor-selective retinoid that is widely used for the early treatment of advanced-stage cutaneous T-cell lymphomas. In this report, we describe a case of successful treatment of advanced primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) with oral bexarotene monotherapy. After the administration of oral bexarotene at a dose of 300 mg/m2/day, all skin lesions and lymph nodes regressed, and complete remission was achieved for 1 year. Our case suggested that bexarotene monotherapy could be one of the possible therapies for the treatment of primary cutaneous PTCL-NOS
%K Primary cutaneous peripheral T-cell lymphoma not otherwise specified
%K Cutaneous T-cell lymphomas
%K Treatment
%K Bexarotene monotherapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903120/